心肾综合征生物标志物研究新进展  

New advances in biomarker research for cardiorenal syndrome

作　　者：刘天承 胡政琪 唐毅[1,2] 刘志斌 何晋 LIU Tiancheng;HU Zhengqi;TANG Yi;LIU Zhibin;HE Jin(Department of Cardiology,Hunan Provincial People's Hospital,The First Affiliated Hospital of Hunan Normal University,Changsha,410005,China;Clinical Medicine Research Center of Heart Failure of Hunan Province)

机构地区：[1]湖南师范大学附属第一医院湖南省人民医院心血管内科,长沙410005 [2]湖南省心力衰竭临床医学研究中心

出　　处：《临床心血管病杂志》2025年第1期20-23,共4页Journal of Clinical Cardiology

基　　金：湖南省科技创新计划项目(No:2020SK50923);湖南省卫生健康委科研计划项目(No:202103012371);仁术基金重点培育项目(No:RS2022A12)。

摘　　要：心肾综合征(CRS)是一种心脏和肾脏功能障碍并存的疾病,显著影响患者预后。本文介绍了CRS相关生物标志物,包括利钠肽、致瘤抑制因子-2(suppression of tumorigenicity-2,ST2)、半乳糖凝集素-3(galectin-3,Gal-3)、中性粒细胞明胶酶相关脂质运载蛋白(neutrophil gelatinase-associated lipocalin,NGAL)等的研究新进展,重点探讨其在疾病诊断、预后评估及治疗指导中的作用,并强调了多种标志物联合应用可更准确反映疾病的复杂病理过程,提高诊断和治疗效果。新型标志物为改善CRS患者预后提供了潜在可能,但仍需进一步研究验证其临床价值。Cardiorenal syndrome(CRS)represents a complex pathophysiological disorder characterized by concurrent cardiac and renal dysfunction,significantly impacting patient outcomes.Recent advances in biomarker research have enhanced our understanding of CRS pathophysiology and improved patient care.This review examines current evidence regarding established and emerging CRS biomarkers,with particular focus on natriuretic peptides,soluble ST2,galectin-3(Gal-3),and neutrophil gelatinase-associated lipocalin(NGAL).These biomarkers demonstrate significant utility in disease diagnosis,prognostic assessment,and therapeutic monitoring.Multi-marker strategies show promise in capturing the complex pathophysiology of CRS,potentially leading to improved diagnostic accuracy and treatment optimization.While novel biomarkers offer encouraging prospects for enhancing patient outcomes,additional large-scale clinical validation studies are needed to establish their definitive role in clinical practice.

关 键 词：心肾综合征 生物标志物 心力衰竭 慢性肾脏病 急性肾损伤 

分 类 号：R541.6[医药卫生—心血管疾病]